Show simple item record

dc.contributor.authorKourtesi, Christina
dc.contributor.authorBall, Anthony R
dc.contributor.authorHuang, Ying-Ying
dc.contributor.authorJachak, Sanjay M
dc.contributor.authorVera, D Mariano A
dc.contributor.authorKhondkar, Proma
dc.contributor.authorGibbons, Simon
dc.contributor.authorHamblin, Michael
dc.contributor.authorTegos, George
dc.date.accessioned2013-11-07T16:04:52Z
dc.date.issued2013
dc.identifier.citationKourtesi, Christina, Anthony R Ball, Ying-Ying Huang, Sanjay M Jachak, D Mariano A Vera, Proma Khondkar, Simon Gibbons, Michael R Hamblin, and George P Tegos. 2013. Microbial efflux systems and inhibitors: approaches to drug discovery and the challenge of clinical implementation. The Open Microbiology Journal 7: 34-52.en_US
dc.identifier.issn1874-2858en_US
dc.identifier.urihttp://nrs.harvard.edu/urn-3:HUL.InstRepos:11298019
dc.description.abstractConventional antimicrobials are increasingly ineffective due to the emergence of multidrug-resistance among pathogenic microorganisms. The need to overcome these deficiencies has triggered exploration for novel and unconventional approaches to controlling microbial infections. Multidrug efflux systems (MES) have been a profound obstacle in the successful deployment of antimicrobials. The discovery of small molecule efflux system blockers has been an active and rapidly expanding research discipline. A major theme in this platform involves efflux pump inhibitors (EPIs) from natural sources. The discovery methodologies and the available number of natural EPI-chemotypes are increasing. Advances in our understanding of microbial physiology have shed light on a series of pathways and phenotypes where the role of efflux systems is pivotal. Complementing existing antimicrobial discovery platforms such as photodynamic therapy (PDT) with efflux inhibition is a subject under investigation. This core information is a stepping stone in the challenge of highlighting an effective drug development path for EPIs since the puzzle of clinical implementation remains unsolved. This review summarizes advances in the path of EPI discovery, discusses potential avenues of EPI implementation and development, and underlines the need for highly informative and comprehensive translational approaches.en_US
dc.language.isoen_USen_US
dc.publisherBentham Openen_US
dc.relation.isversionofdoi:10.2174/1874285801307010034en_US
dc.relation.hasversionhttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC3617545/pdf/en_US
dash.licenseLAA
dc.subjectAntimicrobial resistanceen_US
dc.subjectmultidrug efflux systemsen_US
dc.subjectnatural efflux pump inhibitorsen_US
dc.subjectphoto inactivationen_US
dc.subjectdual action antimicrobialsen_US
dc.subjectbiofilmsen_US
dc.subjectvirulence.en_US
dc.titleMicrobial Efflux Systems and Inhibitors: Approaches to Drug Discovery and the Challenge of Clinical Implementationen_US
dc.typeJournal Articleen_US
dc.description.versionVersion of Recorden_US
dc.relation.journalThe Open Microbiology Journalen_US
dash.depositing.authorHamblin, Michael
dc.date.available2013-11-07T16:04:52Z
dc.identifier.doi10.2174/1874285801307010034*
dash.contributor.affiliatedTegos, George
dash.contributor.affiliatedHamblin, Michael
dc.identifier.orcid0000-0001-6431-4605


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record